Cargando…
Anti-tumor effects and potential therapeutic response biomarkers in α-emitting meta-(211)At-astato-benzylguanidine therapy for malignant pheochromocytoma explored by RNA-sequencing
Targeted α-particle therapy is a promising option for patients with malignant pheochromocytoma. Recent observations regarding meta-(211)At-astato-benzylguanidine ((211)At-MABG) in a pheochromocytoma mouse model showed a strong anti-tumor effect, though the molecular mechanism remains elusive. Here,...
Autores principales: | Ohshima, Yasuhiro, Kono, Nobuaki, Yokota, Yuichiro, Watanabe, Shigeki, Sasaki, Ichiro, Ishioka, Noriko S., Sakashita, Tetsuya, Arakawa, Kazuharu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485192/ https://www.ncbi.nlm.nih.gov/pubmed/31037122 http://dx.doi.org/10.7150/thno.30353 |
Ejemplares similares
-
Antitumor effects of radionuclide treatment using α-emitting meta-(211)At-astato-benzylguanidine in a PC12 pheochromocytoma model
por: Ohshima, Yasuhiro, et al.
Publicado: (2018) -
Enhancing the Therapeutic Effect of 2-(211)At-astato-α-methyl-L-phenylalanine with Probenecid Loading
por: Hanaoka, Hirofumi, et al.
Publicado: (2021) -
OR03-01 Effects Of Alpha-emitting Meta-(211)At-astato-benzylguanidine ((211)At-MABG) Compared To (131)I-meta-iodobenzylguanidine ((131)I-MIBG) on Tumor Growth Suppression in a Pheochromocytoma Mouse Model
por: Yoshinaga, Keiichiro, et al.
Publicado: (2020) -
Manual on the proper use of meta-[(211)At] astato-benzylguanidine ([(211)At] MABG) injections in clinical trials for targeted alpha therapy (1st edition)
por: Ukon, Naoyuki, et al.
Publicado: (2022) -
Synthesis of [(211)At]4-astato-L-phenylalanine by dihydroxyboryl-astatine substitution reaction in aqueous solution
por: Shirakami, Yoshifumi, et al.
Publicado: (2021)